C-RAD is proposing Prof. Dr. Frank Lohr as a new Board Member.
At the extra shareholder meeting on October 30th 2013 C-RAD will propose Prof. Dr. Frank Lohr to become the new member of the board.
Frank Lohr is currently Vice Chairman in the radiation oncology department at the University Medical Center in Mannheim, Germany. After his dissertation at the German Cancer Research Center he worked as a researcher at Duke University in the US. In 2002 he started his career at the University Medical Center in Mannheim, where he became 2004 the vice chairman of the Radiation Oncology department and 2005 Adjunct Professor.
Frank Lohr will replace Prof. Dr. Anders Brahme in the board. Anders Brahme will leave the board on his own wish.
Bengt Lind agreed to continue to work in the board.
Börje Bengtsson, Chairman of the board, C-RAD AB:
“I would be glad to welcome Frank Lohr in the C-RAD board. His broad clinical expertise as well as his international contacts within the research community will give valuable input to the successful work of the board. I would like to thank Anders Brahme for his work and his important contribution to build up the company.”
About C-RAD
C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Numbers of employees are currently 29 people. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company’s first product, the C-RAD SentinelTM, started in 2007. Cooperation agreements have been signed with the Swedish company Elekta, the US company Varian and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has founded three companies for direct sales, C-RAD Incorporated in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD has invested in 29 % of the laser company Cyrpa and with an option to acquire the remaining 71 %. C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier.
For more information on C-RAD, please visit www.c-rad.com.
For further information:
Tim Thurn, CEO C-RAD AB, Phone +46-18-666931, E-mail investors@c-rad.com
